AtaiBeckley
ATAI
0.00
0.00
0.00%
AtaiBeckley
US · ATAI
#2575 by market cap
Listed 2021
0.00
0.00
0.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 09:30
About AtaiBeckley
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
- CEO
- Mr. Srinivas G. Rao, M.D.,PhD
- Employees
- 117
- Fiscal year end
- 12-31
- Website
- ataibeckley.com
Company profile
- Exchange
- US
- Symbol
- ATAI
- Market-cap rank
- #2575
- Listing date
- 2021-06-18
- Market cap
- 0
- Float cap
- 0
- Shares out
- 370.86M
- Float shares
- 308.41M
Sectors & themes
Quote time 2026-11-20 09:30:00 · For reference only, not investment advice and not tailored to your situation.
AtaiBeckley discussion 0 comments